Bibliography
- KLEBL BM: Stacking up the armoury against viruses. Drug Discov. Today (2004) 9:162–164.
- RANDALL G, GRAKOUI A, RICE CM: Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc. Natl. Acad. Sci. USA (2003) 100:235–240.
- ••First report on the use of siRNA in thereplicon system
- WILSON JA, JAYASENA S, KHVOROVA A et al.: RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc. Natl. Acad. Sci. USA (2003) 100:2783–2788.
- BARTENSCHLAGER R: Hepatitis C virus replicons: potential role for drug development. Nat. Rev Drug Discov. (2002) 1:911–916.
- MERCER DF, SCHILLER DE, ELLIOTT JF et al: Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. (2001) 7:927–933.
- •One of the two available animal models for HCV replication.
- VERRIER FC, CHARNEAU P, ALTMEYER R, LAURENT S, BORMAN AM, GIRARD M: Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate. Proc. Natl. Acad. Sci. USA (1997) 94:9326–9331.
- ••CCR5 as an important co-receptor forHIV entry.
- PANCHOLI P, LEE DH, LIU Q et al: DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology (2001) 33(2):448–454.
- KLEBL BM, KURTENBACH A, SALASSIDIS K, DAUB H, HERGET T: Host cell targets in HCV therapy: Novel strategy or proven practice? Antiviral Chem. Chemother. (2005) (In press).
- •Review with a focus on comparing direct and indirect antiviral targets in hepatitis C.
- LAMARRE D, ANDERSON PC, BAILEY M et al.: An N53 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature (2003) 426:186–189.
- ••Generation of the HCV PI BILN- 192061and its clinical proof-of-concept
- FOY E, LI K, WANG C et al: Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science (2003) 300:1145–1148.
- MORBITZER M, HERGET T: Expression of gastrointestinal glutathione peroxidase is inversely correlated to the presence of hepatitis C virus subgenomic RNA in human liver cells. 1 Biol. Chem. (2004) (In press)
- KING NM, PRABU-JEYABALAN M, NALIVAIKA EA, WIGERINCK P, DE BETHUNE MP, SCHIFFER CA: Structural and thermodynamic basis for the binding of TMC-114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. (2004) 78:12012–12021.
- ANDRIES K, AZIJN H, THIELEMANS T et al: TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. (2004) 48:4680–4686.
- GRUZDEV B, RAKHMANOVA A, DOUBOVSKAYA E et al: A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS (2003) 17:2487–2494.
- GAZZARD BG, POZNIAK AL, ROSENBAUM W et al.: An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS (2003) 17:F49–F54.
- HENKE BR, AQUINO CJ, BIRKEMO LSet al: Optimization of 3-(1H-indazol-3-ylmethy6-1,5-benzodiazepines as potent, orally active CCK-A agonists../. Med. Chem. (1997) 40:2706–2725.